HilleVax, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLVX research report →
Companywww.hillevax.com
HilleVax, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
- CEO
- Robert M. Hershberg
- IPO
- 2022
- Employees
- 14
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $104.76M
- P/E
- -2.31
- P/S
- 0.00
- P/B
- 0.71
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -29.97%
- ROIC
- -29.43%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-147,267,000 · -19.18%
- EPS
- $-3.00 · 1.32%
- Op Income
- $-155,291,000
- FCF YoY
- -12.08%
Performance & Tape
- 52W High
- $2.17
- 52W Low
- $1.34
- 50D MA
- $2.09
- 200D MA
- $1.92
- Beta
- 0.77
- Avg Volume
- 718.71K
Get TickerSpark's AI analysis on HLVX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 25 | TAKEDA PHARMACEUTICAL CO LTD | other | 6,724,000 |
| Sep 17, 25 | Frazier Life Sciences X, L.P. | other | 17,199 |
| Sep 17, 25 | HERSHBERG ROBERT | other | 1,101,498 |
| Sep 17, 25 | Cocero Nanette | other | 17,199 |
| Sep 17, 25 | HILLEMAN JERYL L | other | 59,224 |
| Sep 17, 25 | Chu Shelley | other | 17,199 |
| Sep 17, 25 | Dubin Gary | other | 17,199 |
| Sep 17, 25 | Kohli Aditya | other | 698,171 |
| Sep 17, 25 | Gerberding Julie L. | other | 59,224 |
| Sep 17, 25 | Maltbie Shane | other | 83,738 |
Our HLVX Coverage
We haven't published any research on HLVX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HLVX Report →